The superiority of IFN-l as a therapeutic candidate to control acute influenza viral lung infection

Sujin Kim, Min Ji Kim, Chang Hoon Kim, Ju Wan Kang, Ha Kyung Shin, Dong Young Kim, Tae Bin Won, Doo Hee Han, Chae Seo Rhee, Joo Heon Yoon, Hyun Jik Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Here, we studied the IFN-regulated innate immune response against influenza A virus (IAV) infection in the mouse lung and the therapeutic effect of IFN-l2/3 in acute IAV lung infection. For viral infections, IAV (WS/33, H1N1, PR8 H1N1, H5N1) were inoculated into wild-Type mice by intranasal delivery, and IAV mRNA level and viral titer were measured. To compare the antiviral effect of IFNs in vivo in the lung, neutralizing antibodies and recombinant IFNs were used. After intranasal inoculation of IAV into mice, viral infection peaked at 7 days postinfection, and the IAV titer also reached its peak at this time. We found that IFN-b and IFN-l2/3 were preferentially induced after IAV infection and the IFNl2/ 3-mediated innate immune response was specifically required for the induction of IFN-stimulated genes (ISGs) transcription in the mouse respiratory tract. Neutralization of secreted IFN-l2/3 aggravated acute IAV lung infection in mice with intact IFN-b induction; consistent with this finding, the transcription of ISGs was significantly reduced. Intranasal administration of IFN-l2/3 significantly suppressed various strains of IAV infection, including WS/33 (H1N1), PR (H1N1), and H5N1 in the mouse lung, and was accompanied by greater up-regulation of ISGs. Taken together, our data indicate that the IFN-l2/3-mediated innate immune response is necessary to protect the lungs from IAV infection, and intranasally delivered IFN-l2/3 has the potential to be a useful therapeutic strategy for treating acute IAV lung infection.

Original languageEnglish
Pages (from-to)202-212
Number of pages11
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume56
Issue number2
DOIs
Publication statusPublished - 2017 Feb

Fingerprint

Influenza A virus
Virus Diseases
Viruses
Human Influenza
Lung
Innate Immunity
Therapeutics
Genes
Transcription
Intranasal Administration
Therapeutic Uses
Neutralizing Antibodies
Viral Load
Respiratory System
Antiviral Agents
Up-Regulation
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Clinical Biochemistry
  • Cell Biology

Cite this

Kim, Sujin ; Kim, Min Ji ; Kim, Chang Hoon ; Kang, Ju Wan ; Shin, Ha Kyung ; Kim, Dong Young ; Won, Tae Bin ; Han, Doo Hee ; Rhee, Chae Seo ; Yoon, Joo Heon ; Kim, Hyun Jik. / The superiority of IFN-l as a therapeutic candidate to control acute influenza viral lung infection. In: American Journal of Respiratory Cell and Molecular Biology. 2017 ; Vol. 56, No. 2. pp. 202-212.
@article{43a9120f032f41e18804637cb8b98cdb,
title = "The superiority of IFN-l as a therapeutic candidate to control acute influenza viral lung infection",
abstract = "Here, we studied the IFN-regulated innate immune response against influenza A virus (IAV) infection in the mouse lung and the therapeutic effect of IFN-l2/3 in acute IAV lung infection. For viral infections, IAV (WS/33, H1N1, PR8 H1N1, H5N1) were inoculated into wild-Type mice by intranasal delivery, and IAV mRNA level and viral titer were measured. To compare the antiviral effect of IFNs in vivo in the lung, neutralizing antibodies and recombinant IFNs were used. After intranasal inoculation of IAV into mice, viral infection peaked at 7 days postinfection, and the IAV titer also reached its peak at this time. We found that IFN-b and IFN-l2/3 were preferentially induced after IAV infection and the IFNl2/ 3-mediated innate immune response was specifically required for the induction of IFN-stimulated genes (ISGs) transcription in the mouse respiratory tract. Neutralization of secreted IFN-l2/3 aggravated acute IAV lung infection in mice with intact IFN-b induction; consistent with this finding, the transcription of ISGs was significantly reduced. Intranasal administration of IFN-l2/3 significantly suppressed various strains of IAV infection, including WS/33 (H1N1), PR (H1N1), and H5N1 in the mouse lung, and was accompanied by greater up-regulation of ISGs. Taken together, our data indicate that the IFN-l2/3-mediated innate immune response is necessary to protect the lungs from IAV infection, and intranasally delivered IFN-l2/3 has the potential to be a useful therapeutic strategy for treating acute IAV lung infection.",
author = "Sujin Kim and Kim, {Min Ji} and Kim, {Chang Hoon} and Kang, {Ju Wan} and Shin, {Ha Kyung} and Kim, {Dong Young} and Won, {Tae Bin} and Han, {Doo Hee} and Rhee, {Chae Seo} and Yoon, {Joo Heon} and Kim, {Hyun Jik}",
year = "2017",
month = "2",
doi = "10.1165/rcmb.2016-0174OC",
language = "English",
volume = "56",
pages = "202--212",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "2",

}

The superiority of IFN-l as a therapeutic candidate to control acute influenza viral lung infection. / Kim, Sujin; Kim, Min Ji; Kim, Chang Hoon; Kang, Ju Wan; Shin, Ha Kyung; Kim, Dong Young; Won, Tae Bin; Han, Doo Hee; Rhee, Chae Seo; Yoon, Joo Heon; Kim, Hyun Jik.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 56, No. 2, 02.2017, p. 202-212.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The superiority of IFN-l as a therapeutic candidate to control acute influenza viral lung infection

AU - Kim, Sujin

AU - Kim, Min Ji

AU - Kim, Chang Hoon

AU - Kang, Ju Wan

AU - Shin, Ha Kyung

AU - Kim, Dong Young

AU - Won, Tae Bin

AU - Han, Doo Hee

AU - Rhee, Chae Seo

AU - Yoon, Joo Heon

AU - Kim, Hyun Jik

PY - 2017/2

Y1 - 2017/2

N2 - Here, we studied the IFN-regulated innate immune response against influenza A virus (IAV) infection in the mouse lung and the therapeutic effect of IFN-l2/3 in acute IAV lung infection. For viral infections, IAV (WS/33, H1N1, PR8 H1N1, H5N1) were inoculated into wild-Type mice by intranasal delivery, and IAV mRNA level and viral titer were measured. To compare the antiviral effect of IFNs in vivo in the lung, neutralizing antibodies and recombinant IFNs were used. After intranasal inoculation of IAV into mice, viral infection peaked at 7 days postinfection, and the IAV titer also reached its peak at this time. We found that IFN-b and IFN-l2/3 were preferentially induced after IAV infection and the IFNl2/ 3-mediated innate immune response was specifically required for the induction of IFN-stimulated genes (ISGs) transcription in the mouse respiratory tract. Neutralization of secreted IFN-l2/3 aggravated acute IAV lung infection in mice with intact IFN-b induction; consistent with this finding, the transcription of ISGs was significantly reduced. Intranasal administration of IFN-l2/3 significantly suppressed various strains of IAV infection, including WS/33 (H1N1), PR (H1N1), and H5N1 in the mouse lung, and was accompanied by greater up-regulation of ISGs. Taken together, our data indicate that the IFN-l2/3-mediated innate immune response is necessary to protect the lungs from IAV infection, and intranasally delivered IFN-l2/3 has the potential to be a useful therapeutic strategy for treating acute IAV lung infection.

AB - Here, we studied the IFN-regulated innate immune response against influenza A virus (IAV) infection in the mouse lung and the therapeutic effect of IFN-l2/3 in acute IAV lung infection. For viral infections, IAV (WS/33, H1N1, PR8 H1N1, H5N1) were inoculated into wild-Type mice by intranasal delivery, and IAV mRNA level and viral titer were measured. To compare the antiviral effect of IFNs in vivo in the lung, neutralizing antibodies and recombinant IFNs were used. After intranasal inoculation of IAV into mice, viral infection peaked at 7 days postinfection, and the IAV titer also reached its peak at this time. We found that IFN-b and IFN-l2/3 were preferentially induced after IAV infection and the IFNl2/ 3-mediated innate immune response was specifically required for the induction of IFN-stimulated genes (ISGs) transcription in the mouse respiratory tract. Neutralization of secreted IFN-l2/3 aggravated acute IAV lung infection in mice with intact IFN-b induction; consistent with this finding, the transcription of ISGs was significantly reduced. Intranasal administration of IFN-l2/3 significantly suppressed various strains of IAV infection, including WS/33 (H1N1), PR (H1N1), and H5N1 in the mouse lung, and was accompanied by greater up-regulation of ISGs. Taken together, our data indicate that the IFN-l2/3-mediated innate immune response is necessary to protect the lungs from IAV infection, and intranasally delivered IFN-l2/3 has the potential to be a useful therapeutic strategy for treating acute IAV lung infection.

UR - http://www.scopus.com/inward/record.url?scp=85013055152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013055152&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2016-0174OC

DO - 10.1165/rcmb.2016-0174OC

M3 - Article

C2 - 27632156

AN - SCOPUS:85013055152

VL - 56

SP - 202

EP - 212

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 2

ER -